The Emergence of Cyclic Peptides: The Potential of Bioengineered Peptide Drugs

Studies into N- to C-terminal cyclic peptide backbone structures have provided for the lateral transition of important principles and strategies that clearly resonate within the world of bioactive peptides and peptide toxins. The ability to transform peptide biologics into stable and orally active constituents represents a major pharmacological achievement. This progression has been forthcoming and is potentially intensified by the diminishing expectations of current small organic molecule pipelines. While still in the early stages of development, cyclic peptide drug leads have gained the attention of the pharmaceutical industry, however their true potential is still very much unknown.